KEYTRUDA Met Primary Endpoint of EFS as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced SCCHN October 15, 2024
Interim data from Ph 1 clinical study of misetionamide (GP-2250) in combination with gemcitabine in patients with pancreatic adenocarcinoma announced October 15, 2024
Ph 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study in patients with R/R multiple myeloma announced October 15, 2024
Updated Ph 1b Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients announced; upcoming SUPRAME Ph 3 Trial to be registrational study October 15, 2024
Autologous Dendritic Cell Vaccine DOC1021 Yields 93% 12-Month Survival for GBM Patients October 8, 2024
ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in OS compared to enzalutamide in patients with mCSPC October 8, 2024
36-Month OS Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation Announced October 8, 2024
Preliminary safety data from the Ph 1b portion of the BGBC016 study in 1L NSCLC patients announced October 8, 2024
Positive Interim Ph 1 Results for P-BCMA-ALLO1 with High ORR in Heavily Pretreated RRMM Patients Reported October 8, 2024
Interim Ph 2 Data for GRANITE Neoantigen Targeting Immunotherapy in 1L Metastatic MSS CRC Announced October 8, 2024
Ph 1 Data of Concurrent Paxalisib + RT in Patients with Solid Tumor Brain Mets or Leptomeningeal Mets Harboring PI3K Pathway Mutations announced October 8, 2024
CARVYKTI significantly extends OS vs standard therapies for patients with multiple myeloma as early as second line October 2, 2024
DARZALEX FASPRO-based quadruplet regimen significantly improves MRD negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned October 1, 2024
Significant New Data from Ph 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer Announced October 1, 2024
Initial Ph 2 Data of BDTX-1535 in Patients with Recurrent EGFRm NSCLC with Classical, Non-classical, and C797S Resistance Mutations Announced October 1, 2024
Positive Initial Safety, Tolerability, PK, and Preliminary Efficacy Data announced from Ph 1 Trial of PAS-004 in Advanced Cancer October 1, 2024
TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) combo yields high response rates and durable responses in triple-class refractory RRMM patients October 1, 2024
FAILED TRIAL: Ph 3 KEYFORM-007 trial of favezelimab + KEYTRUDA did not meet its primary endpoint of OS in patients with previously treated PD-L1+ve MSS mCRC October 1, 2024
Patritumab Deruxtecan Demonstrated Statistically Significant PFS Improvement vs Chemo in Locally Advanced or Metastatic EGFRm NSCLC in HERTHENA-Lung02 Ph 3 Trial September 24, 2024
